Furthermore, targeting transforming growth factor (TGF)-β, either through inhibition or suppression, could potentially be an effective way to reduce cancer progression and increase the effectiveness of existing anti-tumor therapies such as epidermal growth factor receptor (EGFR)-targeted therapy (Pang et al. 2022). This evidence concerns the gene TGFB1 and cancer.